Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush

Chimerix (NASDAQ:CMRX)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Thursday,RTT News reports. They currently have a $6.00 price objective on the biopharmaceutical company’s stock.

CMRX has been the subject of a number of other reports. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday, August 14th.

Chimerix Stock Performance

Chimerix stock traded down $0.07 during trading hours on Thursday, reaching $0.94. 385,299 shares of the company’s stock traded hands, compared to its average volume of 352,250. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30. The firm’s 50 day moving average is $0.90 and its 200-day moving average is $0.91. The firm has a market capitalization of $83.82 million, a price-to-earnings ratio of -0.98 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same period in the previous year, the business earned ($0.21) EPS. Analysts predict that Chimerix will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CMRX. Koshinski Asset Management Inc. bought a new position in shares of Chimerix during the first quarter worth approximately $42,000. Valeo Financial Advisors LLC increased its holdings in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares in the last quarter. Marshall Wace LLP bought a new position in Chimerix in the 2nd quarter valued at approximately $137,000. Finally, Acadian Asset Management LLC increased its position in Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after acquiring an additional 291,981 shares during the period. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.